Pursuant to the provisions of article 82 of the Spanish Securities Market Act (Ley del Mercado de Valores), GRIFOLS, S.A. (the "Company") informs that the Spanish Agency for Drugs and Health products has authorized Araclon Biotech S.L., a company majority owned by Grifols, to start phase I of a clinical trial for assessing the tolerance and safety of the ABvac40 vaccine for patients with mild or moderate Alzheimer's disease.

In Barcelona, on this 18th September 2013

Raimon Grifols Roura  
Secretary to the Board of Directors